Experience in the Province of Buenos Aires

Abstract

The experience in the management of PRODIABA between 2019 and 2023 is described along three axes: access, care and medications.

Regarding access, the number of people registered in PRODIABA increased from 47,000 to 78,000, which represents an increase of 65.9%; in the context of the COVID-19 pandemic and post-pandemic, different strategies were carried out, such as training for health teams, the distribution of graphic materials, the updating of the program's website and, fundamentally, the joint work with the 12 health regions and provincial effectors with municipalities, national effectors, hospitals in CABA, territorial and telecare devices (CETEC) that contributed to the dissemination of access circuits and agile communication for conflict resolution for the different programmatic lines.

About care, the type 2 diabetes care line for adults was created, based on the scientific evidence and involving the participation of different areas of the Ministry and the validation of scientific societies and the Ministry of Health of Argentina. This care line is an ordering proposal for addressing the pathology in this population that seeks to avoid therapeutic inertia and also be a work tool at the local level during its implementation in conjunction with HEARTS-D strategy.

Finally in respect of medications, access to insulin pens was strengthened during this period and the Gliclazide 60 mg modified release, Liraglutide and Empagliflozin were incorporated into vademecum. At the same time, the necessary development for the public production of Gliclazide was started together with the National University of La Plata and the Biological Institute “Tomás Perón”, which will be added to the production of Metformin, whose has doubled over these years from 2.5 million to more than 5 million pills per month. The provincial Health Ministry began working on the topic of medication in terms of selection, acquisition and logistics of distribution in an integrated manner.